Dec 11, 2017
|
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
|
|
Dec 05, 2017
|
MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
|
|
Nov 15, 2017
|
MacroGenics Names Dr. Jay Siegel to its Board of Directors
|
|
Nov 13, 2017
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Nov 10, 2017
|
MacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017
|
|
Nov 08, 2017
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results
|
|
Nov 01, 2017
|
MacroGenics Announces Date of Third Quarter 2017 Financial Results Conference Call
|
|
Nov 01, 2017
|
MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting
|
|
Oct 25, 2017
|
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
|
|
Sep 10, 2017
|
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Presented at ESMO Congress 2017
|
|
Sep 05, 2017
|
MacroGenics Advances Two First-in-Class Clinical DART® Molecules
|
|
Aug 31, 2017
|
MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen
|
|
Aug 30, 2017
|
MacroGenics to Participate in Three Investor Conferences in September
|
|
Aug 09, 2017
|
MacroGenics to Present at the Wedbush PacGrow Healthcare Conference
|
|
Aug 02, 2017
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results
|
|
Jul 26, 2017
|
MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call
|
|
Jul 17, 2017
|
Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017
|
|
Jun 17, 2017
|
MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)
|
|
May 03, 2017
|
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results
|
|
Apr 27, 2017
|
MacroGenics Announces Registered Direct Offering of Common Stock
|
|
Apr 26, 2017
|
MacroGenics to Present at Two Upcoming Investor Conferences in May
|
|
Apr 25, 2017
|
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
|
|
Mar 31, 2017
|
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017
|
|
Mar 29, 2017
|
MacroGenics to Present at the Needham Healthcare Conference
|
|
Feb 28, 2017
|
MacroGenics Provides Update on Corporate Progress and 2016 Financial Results
|
|